<DOC>
	<DOCNO>NCT00510601</DOCNO>
	<brief_summary>A pilot study examine effect LDL-Apheresis patient Stage III Congestive Heart Failure . Study hypothesis : Decreased blood viscosity receive LDL-apheresis decrease workload heart improve symptom associate progression Congestive Heart Failure</brief_summary>
	<brief_title>Treating Congestive Heart Failure Using Device Remove Cholesterol</brief_title>
	<detailed_description>Patients qualify study receive 7 bi-weekly LDL-Apheresis treatment Kaneka Liposorber device . Patients assess CHF symptom use KC Cardiomyopathy questionnaire prior treatment . Blood level certain index relate CHF safety profile lab draw first last treatment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male Female , age 18 85 year old . If female , must guarantee pregnancy occur duration study Presence Left ventricular systolic dysfunction due ischemic nonischemic cardiomyopathy symptom New York Heart Association Class III chronic Heart failure ( CHF ) Left ventricular ejection fraction ( LVEF ) â‰¤ 35 % measure radionuclide angiography Subject must optimal conventional heart failure therapy include Betablocker target maximally tolerated dos least 3 month prior entry study , and/or angiotension receptor blocker ( ARB ) least 30 day prior study entry . Subjects ACE inhibitor , approval physician , switch ARB one week initiate apheresis Other optimal conventional therapy take least 30 day prior initiation apheresis Subject able complete 6minute walk test Kansas City Congestive Heart Failure Quality Life Questionnaire ( KCCQ ) Not currently , plan participate study Age &lt; 18 year , &gt; 85 year age Poor venous access CHF due , associate , uncorrected primary valvular disease , uncorrected thyroid disease , obstructive/hypertrophic cardiomyopathy , pericardial disease , amyloidosis , active myocarditis , malfunction artificial heart valve , uncorrected congenital heart disease , primary pulmonary hypertension Subject undergone cardiac revascularization , valvular surgery , biventricular resynchronization procedure within six month prior initiation apheresis treatment Subject list transplantation expect transplant within 6 month initiation apheresis treatment Subject myocardial infarction within 6 month prior initiation apheresis treatment Subject electrocardiogram ( ECG ) record initial screen show particular abnormality Subject sustain VT , unless precipitate event acute myocardial infarction , induction catheter replacement , electrophysiology procedure , address placement automatic implantable cardiac defibrillator ( AICD ) Subject AICD fire ventricular arrhythmia within 90 day initial visit Subject unstable angina Subject mechanical assist device Subject evidence concomitant disease may interfere natural course subject underlying heart failure duration study Subject poorly control diabetes mellitus Subject currently take study prohibit medication Subject unable tolerate Beta blocker therapy asthma , heart rate &lt; 55 bpm , presence second third degree heart block without implant pacemaker , firstdegree heart block PR interval &gt; 220 millisecond Subject active disease , opinion Investigator , may adversely affect safety efficacy treatment life span patient Subject history , currently abuse alcohol illicit drug Subject serum potassium &lt; 4.0 mEq/L &gt; 5.5mEq/L initial visit Subject serum digoxin level &gt; 1.2ng/mL time initial visit Subject pregnant risk become pregnant study Subject currently lactate Subject participate clinical drug device trial last 90 day Subject demonstrate noncompliance previous medical regimen Subject currently hospitalize , hemodynamically stable , acute cardiac noncardiac illness require hospitalization Subject unable , unwilling change ACEI ARB Subject know hypersensitivity heparin ethylene oxide Subject known Lowdensity lipoprotein cholesterol ( LDLC ) level &gt; 130mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>